Latest Pharmaceutical Services News

Careteq Limited has agreed to sell its Embedded Health Solutions business for $5 million, aiming to strengthen its balance sheet and focus on expanding its home medication review platform amid ongoing tax disputes.

Adheris Health has expanded its operating cost reduction program, aiming for more than 30% savings by FY27, while refocusing on high-growth pharmaceutical categories and enhancing its AI-powered patient engagement platform.

Resonance Health has reported record half-year revenue and strong progress in clinical trials, alongside promising new technology deployments set to enhance its global footprint.

ALS Limited has posted a robust first half for FY26 with underlying EBIT growth of 14.7%, driven by strong performance in its Commodities segment and improved Life Sciences results. The company also raised its interim dividend and updated its growth outlook for the year.

Resonance Health reports positive cash flow and significant progress in its clinical trials and Software-as-a-Medical Device business, setting the stage for growth in new international markets.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Resonance Health reports a solid quarter with key clinical trial milestones, expansion of trial sites, and multi-year Software-as-a-Medical Device contracts, underpinning a positive cashflow outlook.

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.

Sigma Healthcare has received Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in its strategic expansion. The scheme is set to become legally effective on February 4, 2025, with implementation expected by February 12.